CPI-1189
Phase 2Small molecule
CPI-1189 is one of 8 small molecule programs targeting AIDS dementia. It is currently in Phase 2.
1
Indications
2
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in AIDS Dementia
#DrugCompanyPhaseTrials
1Selzentry
GSKApproved
Feraheme
AAzurity Pharmaceuticals
Approved
Retrovir
BBp Consulting, Inc
Phase 3
Ziagen
GSKPhase 3
Zerit
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Videx
Bristol-Myers SquibbPhase 2
Namenda
AbbViePhase 2
CPI-1189
CCentaur Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CPI-1189. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCentaur Pharmaceuticals